• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

进行性骨化性纤维发育不良(FOP)患者的微量元素和细胞因子浓度:一项病例对照研究。

Trace element and cytokine concentrations in patients with Fibrodysplasia Ossificans Progressiva (FOP): A case control study.

作者信息

Hildebrand Laura, Gaber Timo, Kühnen Peter, Morhart Rolf, Unterbörsch Heinz, Schomburg Lutz, Seemann Petra

机构信息

Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Germany.

Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Germany.

出版信息

J Trace Elem Med Biol. 2017 Jan;39:186-192. doi: 10.1016/j.jtemb.2016.10.001. Epub 2016 Oct 4.

DOI:10.1016/j.jtemb.2016.10.001
PMID:27908413
Abstract

Fibrodysplasia Ossificans Progressiva (FOP) is a rare inherited disease characterized by progressive heterotopic ossification. Disease onset, severity and symptoms vary between FOP patients, as does the frequency and activity of so-called flare-ups, during which tendons, ligaments, muscle and soft tissue are replaced by bone. Traumata, infections or other stressors are known inducers of flare-ups, and the hormone Activin A may be involved in disease activity; however, reliable biomarkers for FOP activity are missing, and the basal trace element and inflammatory state of patients are unknown. We hypothesized that FOP patients develop characteristic deficiencies in inflammation-related trace elements and display a chronically increased inflammatory cytokine level, collectively aggravating disease course and flare-up risk. Serum samples from 15 FOP patients and 25 relatives were collected under highest quality standards. Concentrations of Cu, Se and Zn were determined by total reflection X-ray fluorescence, and 27 cytokines along with Activin A by specific antibody-based techniques. Data were tested for normal distribution and analyzed by parametric or non-parametric tests. Concentrations of Se and Cu were not different between the groups, while Zn levels were slightly higher in FOP as compared to controls (1110±251 vs. 970±176ng/ml, P=0.04). The average concentrations of cytokines and Activin A were not different. When focusing on the two patients with self-reported flare-ups, again no obvious differences were noted. The cytokines Eotaxin, G-CSF, hbFGF and TNF-α were within the upper half of measured concentrations, and may warrant further longitudinal analyses. Our data do not support the hypothesis that FOP patients display a characteristic pattern of trace elements or have a generally increased tone of pro-inflammatory cytokines.

摘要

进行性骨化性纤维发育不良(FOP)是一种罕见的遗传性疾病,其特征为进行性异位骨化。FOP患者的发病时间、严重程度和症状各不相同,所谓的病情发作频率和活动情况也是如此,在此期间肌腱、韧带、肌肉和软组织会被骨组织替代。创伤、感染或其他应激源是已知的病情发作诱因,激活素A激素可能参与疾病活动;然而,目前缺乏用于评估FOP疾病活动的可靠生物标志物,患者的基础微量元素和炎症状态也尚不明确。我们推测,FOP患者在与炎症相关的微量元素方面存在特征性缺乏,且炎症细胞因子水平长期升高,这些因素共同加剧了疾病进程和病情发作风险。我们按照最高质量标准采集了15例FOP患者和25名亲属的血清样本。通过全反射X射线荧光法测定铜、硒和锌的浓度,采用基于特异性抗体的技术测定27种细胞因子以及激活素A的浓度。对数据进行正态分布检验,并通过参数检验或非参数检验进行分析。两组之间硒和铜的浓度没有差异,而FOP患者的锌水平略高于对照组(1110±251对970±176ng/ml,P=0.04)。细胞因子和激活素A的平均浓度没有差异。聚焦于两名自述有病情发作的患者时,同样未发现明显差异。嗜酸性粒细胞趋化因子、粒细胞集落刺激因子、人碱性成纤维细胞生长因子和肿瘤坏死因子-α的浓度处于所测浓度的上半部分,可能需要进一步进行纵向分析。我们的数据不支持FOP患者存在微量元素特征性模式或促炎细胞因子总体水平升高这一假设。

相似文献

1
Trace element and cytokine concentrations in patients with Fibrodysplasia Ossificans Progressiva (FOP): A case control study.进行性骨化性纤维发育不良(FOP)患者的微量元素和细胞因子浓度:一项病例对照研究。
J Trace Elem Med Biol. 2017 Jan;39:186-192. doi: 10.1016/j.jtemb.2016.10.001. Epub 2016 Oct 4.
2
Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial.成纤维细胞性骨化发育不良成人患者flare-ups 的特征及 garetosmab 的影响:LUMINA-1 试验的一项随机、双盲、安慰剂对照的事后分析。
J Bone Miner Res. 2024 Sep 26;39(10):1486-1492. doi: 10.1093/jbmr/zjae140.
3
Elevated plasma RANTES in fibrodysplasia ossificans progressiva - A novel therapeutic target?纤维发育不良性骨化性进展症患者血浆 RANTES 升高——新的治疗靶点?
Med Hypotheses. 2019 Oct;131:109313. doi: 10.1016/j.mehy.2019.109313. Epub 2019 Jul 20.
4
The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment.进行性骨化性纤维发育不良(FOP)发作的自然史:一项全面的全球评估。
J Bone Miner Res. 2016 Mar;31(3):650-6. doi: 10.1002/jbmr.2728. Epub 2015 Nov 14.
5
Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes.纤维性骨发育不良进展性的自然史:注释基线表型的横断面分析。
Orphanet J Rare Dis. 2019 May 3;14(1):98. doi: 10.1186/s13023-019-1068-7.
6
Acute unilateral hip pain in fibrodysplasia ossificans progressiva (FOP).进行性骨化性纤维发育不良(FOP)中的急性单侧髋关节疼痛。
Bone. 2018 Apr;109:115-119. doi: 10.1016/j.bone.2017.08.009. Epub 2017 Aug 16.
7
Post-COVID-19 exacerbation of fibrodysplasia ossificans progressiva with multiple flare-ups and extensive heterotopic ossification in a 45-year-old female patient.一名45岁女性患者在感染新冠病毒后,进行性骨化性纤维发育不良病情加重,出现多次病情发作及广泛的异位骨化。
Rheumatol Int. 2021 Aug;41(8):1495-1501. doi: 10.1007/s00296-021-04911-6. Epub 2021 Jun 10.
8
Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP).进行性骨化性纤维发育不良(FOP)患者的纵向报告移动性评估。
Bone. 2018 Apr;109:158-161. doi: 10.1016/j.bone.2017.06.005. Epub 2017 Jun 6.
9
Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva.长期使用白细胞介素-1 抑制剂可减少进行性骨化性纤维发育不良患者的发作活动。
Rheumatology (Oxford). 2024 Sep 1;63(9):2597-2604. doi: 10.1093/rheumatology/keae255.
10
Activin-A Induces Fewer, but Larger Osteoclasts From Monocytes in Both Healthy Controls and Fibrodysplasia Ossificans Progressiva Patients.激活素-A 可诱导健康对照者和进行性骨化性纤维发育不良患者的单核细胞生成数量较少但体积较大的破骨细胞。
Front Endocrinol (Lausanne). 2020 Jul 14;11:501. doi: 10.3389/fendo.2020.00501. eCollection 2020.

引用本文的文献

1
[F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders.氟[18F]去铁胺 PET/CT 作为成骨不全性骨纤维发育异常的标志物:从分子机制到骨骼疾病的临床应用。
Biomolecules. 2024 Oct 10;14(10):1276. doi: 10.3390/biom14101276.
2
Performance of simplified methods for quantification of [F]NaF uptake in fibrodysplasia ossificans progressiva.进行性骨化性纤维发育不良中[F]氟化钠摄取定量简化方法的性能
Front Nucl Med. 2024 Jul 22;4:1406947. doi: 10.3389/fnume.2024.1406947. eCollection 2024.
3
Human iPSCs as Model Systems for BMP-Related Rare Diseases.
人诱导多能干细胞作为 BMP 相关罕见病的模型系统。
Cells. 2023 Sep 2;12(17):2200. doi: 10.3390/cells12172200.
4
Diminished muscle integrity in patients with fibrodysplasia ossificans progressiva assessed with at-home electrical impedance myography.应用家庭式电阻抗肌图评估进行性骨化性纤维发育不良患者的肌肉完整性受损。
Sci Rep. 2022 Dec 3;12(1):20908. doi: 10.1038/s41598-022-25610-7.
5
Case Report: Unable to Jump Like a Kangaroo Due to Myositis Ossificans Circumscripta.病例报告:因局限性骨化性肌炎而无法像袋鼠一样跳跃。
Front Vet Sci. 2022 Jul 4;9:886495. doi: 10.3389/fvets.2022.886495. eCollection 2022.
6
Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop.骨化性纤维发育不良进展性:我们已经取得了哪些成就,现在又在哪里?对 2015 年洛伦茨研讨会的跟进。
Front Endocrinol (Lausanne). 2021 Nov 10;12:732728. doi: 10.3389/fendo.2021.732728. eCollection 2021.
7
Rare and intractable fibrodysplasia ossificans progressiva shows different PBMC phenotype possibly modulated by ascorbic acid and propranolol treatment.罕见且难治的进行性骨化性纤维发育不良表现出不同的外周血单核细胞表型,可能受到抗坏血酸和普萘洛尔治疗的调节。
Intractable Rare Dis Res. 2021 Aug;10(3):179-189. doi: 10.5582/irdr.2021.01012.
8
Heterotopic Ossification: A Comprehensive Review.异位骨化:全面综述
JBMR Plus. 2019 Feb 27;3(4):e10172. doi: 10.1002/jbm4.10172. eCollection 2019 Apr.
9
NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification.ACVR1 介导的炎症反应中 NF-κB/MAPK 的激活作用。
JCI Insight. 2018 Nov 15;3(22):122958. doi: 10.1172/jci.insight.122958.
10
Fibrodysplasia ossificans progressiva: Basic understanding and experimental models.进行性骨化性纤维发育不良:基本认识与实验模型
Intractable Rare Dis Res. 2017 Nov;6(4):242-248. doi: 10.5582/irdr.2017.01055.